ARCHIMED Acquires Esperion Therapeutics in Strategic Cardiometabolic Deal

Key Takeaways

• ARCHIMED agreed to acquire Esperion for $3.16 per share in cash—a 58% premium to the April 30, 2026 closing price, per SEC filings
• Shareholders receive contingent value rights (CVRs) for up to $100 million in milestone payments tied to net sales performance
• The FDA approved NEXLETOL (bempedoic acid) in 2020 for LDL-C lowering in statin-intolerant patients
• NEXLIZET combines bempedoic acid with ezetimibe for enhanced cholesterol reduction
• Esperion shareholders approved the merger on July 8, 2026; closing expected Q3 2026

What Is the Structure of the ARCHIMED-Esperion Acquisition?

On May 1, 2026, Esperion Therapeutics entered into an Agreement and Plan of Merger with Essence Parent Inc., an affiliate of ARCHIMED, and Essence MergerCo Inc. Under the agreement, MergerCo will merge with Esperion, with Esperion continuing as a wholly-owned subsidiary of Parent.

The transaction delivers immediate value to Esperion shareholders while positioning the company's commercial assets under specialized healthcare investment management. The deal represents ARCHIMED's continued commitment to healthcare sector investments and builds upon its portfolio of commercial-stage pharmaceutical assets.

How Much Will Esperion Shareholders Receive?

Esperion shareholders receive $3.16 per share in cash at closing. This represents a 58% premium to Esperion's closing share price on April 30, 2026. The upfront cash consideration delivers immediate value realization to public market investors.

Shareholders also receive contingent value rights (CVRs) tied to future net sales milestones. The CVRs entitle holders to participate in up to $100 million in aggregate milestone payments:

Milestone	Trigger	Payment
Sales Milestone 1	Annual U.S. net sales of bempedoic acid products exceed $350 million in 2027	$40 million
Sales Milestone 2	Annual U.S. net sales of bumetanide products reach $160 million by December 31, 2030	$60 million

What Are NEXLETOL and NEXLIZET?

NEXLETOL and NEXLIZET are Esperion's primary commercial assets. Both contain bempedoic acid, an adenosine triphosphate-citrate lyase (ACL) inhibitor.

NEXLETOL (bempedoic acid) tablets received FDA approval in February 2020. The 180 mg oral tablet is indicated as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

NEXLIZET (bempedoic acid and ezetimibe) tablets also received FDA approval in February 2020. The fixed-dose combination tablet contains 180 mg bempedoic acid and 10 mg ezetimibe. It combines ACL inhibition with cholesterol absorption inhibition for patients who need additional LDL-C reduction.

Who Are ARCHIMED and What Is Their Investment Strategy?

ARCHIMED is a global investment firm specializing exclusively in healthcare industries. The firm focuses on small-cap and mid-cap growth buyout transactions across seven targeted sectors within healthcare. ARCHIMED invests between €10 million and €1 billion in leading companies, supporting growth through internationalization, innovation, and mergers and acquisitions.

The acquisition of Esperion aligns with ARCHIMED's strategy of targeting late-stage pharmaceutical assets with established or near-commercial revenue streams. The firm prioritizes sub-sectors within cardiometabolic care due to growing global prevalence of cardiovascular diseases and substantial unmet medical need.

What Does This Acquisition Mean for the Cardiometabolic Market?

The ARCHIMED-Esperion transaction reflects consolidation trends in the biopharmaceutical sector. Specialized investment firms increasingly target commercial-stage companies with differentiated therapeutic platforms in large addressable markets.

Esperion's ACL inhibitor platform offers patients an alternative to statins. This mechanism is particularly valuable for the estimated 10-15% of patients who cannot tolerate statins due to muscle-related side effects. The global market for cholesterol-lowering therapies exceeds $20 billion annually, with significant growth in non-statin alternatives.

When Will the Transaction Close?

The merger is subject to customary closing conditions, including regulatory approvals. Key approvals include clearance under the Hart-Scott-Rodino Act in the United States and the Bundeskartellamt (German antitrust authority). The transaction was expected to close in the third quarter of 2026.

On July 8, 2026, Esperion shareholders held a special meeting and voted to approve the merger agreement. The proposal passed with 135,326,793 votes in favor, 22,750,628 against, and 496,194 abstentions. Following shareholder approval, the remaining closing conditions include regulatory clearances and other customary items.

Upon closing, Esperion will become a privately held company and will delist from the Nasdaq Stock Market. ARCHIMED's healthcare-focused investment approach is expected to provide expanded commercial capabilities, operational improvements, and financial resources for pipeline advancement.

What Pipeline Assets Does Esperion Maintain?

Beyond NEXLETOL and NEXLIZET, Esperion maintains a pipeline focused on cardiometabolic and rare/orphan diseases. The company recently expanded its portfolio through the acquisition of Corstasis Therapeutics and its congestive heart failure treatment, ENBUMYST (bumetanide nasal spray). This product addresses edema associated with congestive heart failure, chronic kidney disease, and liver disease.

The ARCHIMED acquisition provides capital and strategic guidance to advance these earlier-stage programs. The firm's healthcare network may also facilitate strategic partnerships for development and commercialization.

Frequently Asked Questions

Primary Sources

• SEC Form 8-K: Esperion Therapeutics Acquisition Agreement, filed May 1, 2026
• SEC Exhibit 99.1: Press Release: Esperion to Be Acquired by ARCHIMED, May 1, 2026
• FDA Label: NEXLETOL (bempedoic acid) Highlights of Prescribing Information, approved February 2020
• FDA Label: NEXLIZET (bempedoic acid and ezetimibe) Highlights of Prescribing Information, approved February 2020
• Esperion Investor Relations: Shareholder Approval Announcement, July 8, 2026